Gentian Diagnostics AS (GENT.OL) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · Norway · ISIN NO0010748866

Price
38.60 NOK
Market cap
595.30 m NOK
P/E (2025)
44.91
P/S (2025)
3.37
Dividend yield
1.55 %
Net margin
7.51 %
Return on equity (ROE)
6.47 %
Return on assets (ROA)
5.13 %

Gentian Diagnostics AS financials

Fiscal year20242025
Revenue152.07 m NOK176.50 m NOK
Gross profit82.82 m NOK98.20 m NOK
Operating income15.72 m NOK25.45 m NOK
EBIT22.58 m NOK26.34 m NOK
Net income45.29 m NOK13.26 m NOK
Diluted EPS – continuing operations2.87 NOK0.86 NOK

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Gentian Diagnostics AS

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.